Dr. Holly E. Pariury
Claim this profileBanner University Medical Center - Tucson
Expert in Cancer
Expert in Brain Tumor
31 reported clinical trials
69 drugs studied
Area of expertise
1Cancer
Global LeaderStage I
Stage II
Stage IV
2Brain Tumor
Global LeaderStage I
Stage II
MTOR positive
Affiliated Hospitals
Clinical Trials Holly E. Pariury is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
More about Holly E. Pariury
Clinical Trial Related8 years of experience running clinical trials · Led 31 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Holly E. Pariury has experience with
- Cyclophosphamide
- Etoposide
- Doxorubicin Hydrochloride
- Radiation Therapy
- Vincristine Sulfate
- Carboplatin
Breakdown of trials Holly E. Pariury has run
Cancer
Brain Tumor
Non-Hodgkin's Lymphoma
Neuroblastoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Holly E. Pariury specialize in?
Holly E. Pariury focuses on Cancer and Brain Tumor. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage II.
Is Holly E. Pariury currently recruiting for clinical trials?
Yes, Holly E. Pariury is currently recruiting for 8 clinical trials in Tucson Arizona. If you're interested in participating, you should apply.
Are there any treatments that Holly E. Pariury has studied deeply?
Yes, Holly E. Pariury has studied treatments such as Cyclophosphamide, Etoposide, Doxorubicin Hydrochloride.
What is the best way to schedule an appointment with Holly E. Pariury?
Apply for one of the trials that Holly E. Pariury is conducting.
What is the office address of Holly E. Pariury?
The office of Holly E. Pariury is located at: Banner University Medical Center - Tucson, Tucson, Arizona 85719 United States. This is the address for their practice at the Banner University Medical Center - Tucson.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.